世界のドルテグラビル・その併用薬市場 2021：企業別、地域別、種類・用途別

• 英文タイトル：Global Dolutegravir and Its Combination Drug Market 2021 by Company, Regions, Type and Application, Forecast to 2026

• レポートコード：GIR-107A12228 • 出版社/出版日：GlobalInfoResearch / 2021年7月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、106ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥515,040 (USD3,480)	▷ お問い合わせ
Multi User	￥772,560 (USD5,220)	▷ お問い合わせ
Corporate User	￥1,030,080 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

当調査資料では、ドルテグラビル・その併用薬のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。ドルテグラビル・その併用薬の種類別市場規模（ドルテグラビル、アバカビル/ドルテグラビル/ラミブジン、ドルテグラビル/リルピビリン）、用途別市場規模（病院、クリニック、ドラッグセンター、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・ドルテグラビル・その併用薬の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：ViiV Healthcare (GSK)、Adcock Ingram Limited、Aurobindo Pharma、Cipla、Emcure Pharmaceuticals、LAURUS Labs、Mylan、Ranbaxy Pharmaceuticals、Shanghai Desano Pharmaceuticals、JNJ ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：ドルテグラビル、アバカビル/ドルテグラビル/ラミブジン、ドルテグラビル/リルピビリン ・用途別分析2016年-2026年：病院、クリニック、ドラッグセンター、その他 ・ドルテグラビル・その併用薬の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・ドルテグラビル・その併用薬のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・ドルテグラビル・その併用薬のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・ドルテグラビル・その併用薬の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・ドルテグラビル・その併用薬の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論

The Dolutegravir and Its Combination Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Dolutegravir and Its Combination Drug size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Dolutegravir and Its Combination Drug market size is expected to grow at a CAGR of xx% for the next five years.

Market segmentation
Dolutegravir and Its Combination Drug market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
Dolutegravir
Abacavir/Dolutegravir/Lamivudine
Dolutegravir/Rilpivirine

Market segment by Application, can be divided into
Hospital
Clinic
Drug Center
Other

Market segment by players, this report covers
ViiV Healthcare (GSK)
Adcock Ingram Limited
Aurobindo Pharma
Cipla
Emcure Pharmaceuticals
LAURUS Labs
Mylan
Ranbaxy Pharmaceuticals
Shanghai Desano Pharmaceuticals
JNJ

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

レポート目次

---

1 Market Overview
1.1 Product Overview and Scope of Dolutegravir and Its Combination Drug
1.2 Classification of Dolutegravir and Its Combination Drug by Type
1.2.1 Overview: Global Dolutegravir and Its Combination Drug Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Dolutegravir and Its Combination Drug Revenue Market Share by Type in 2020
1.2.3 Dolutegravir
1.2.4 Abacavir/Dolutegravir/Lamivudine
1.2.5 Dolutegravir/Rilpivirine
1.3 Global Dolutegravir and Its Combination Drug Market by Application
1.3.1 Overview: Global Dolutegravir and Its Combination Drug Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Drug Center
1.3.5 Other
1.4 Global Dolutegravir and Its Combination Drug Market Size & Forecast
1.5 Global Dolutegravir and Its Combination Drug Market Size and Forecast by Region
1.5.1 Global Dolutegravir and Its Combination Drug Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Dolutegravir and Its Combination Drug Market Size by Region, (2016-2021)
1.5.3 North America Dolutegravir and Its Combination Drug Market Size and Prospect (2016-2026)
1.5.4 Europe Dolutegravir and Its Combination Drug Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Dolutegravir and Its Combination Drug Market Size and Prospect (2016-2026)
1.5.6 South America Dolutegravir and Its Combination Drug Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Dolutegravir and Its Combination Drug Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Dolutegravir and Its Combination Drug Market Drivers
1.6.2 Dolutegravir and Its Combination Drug Market Restraints
1.6.3 Dolutegravir and Its Combination Drug Trends Analysis
2 Company Profiles
2.1 ViiV Healthcare (GSK)
2.1.1 ViiV Healthcare (GSK) Details
2.1.2 ViiV Healthcare (GSK) Major Business
2.1.3 ViiV Healthcare (GSK) Dolutegravir and Its Combination Drug Product and Solutions
2.1.4 ViiV Healthcare (GSK) Dolutegravir and Its Combination Drug Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 ViiV Healthcare (GSK) Recent Developments and Future Plans
2.2 Adcock Ingram Limited
2.2.1 Adcock Ingram Limited Details
2.2.2 Adcock Ingram Limited Major Business
2.2.3 Adcock Ingram Limited Dolutegravir and Its Combination Drug Product and Solutions
2.2.4 Adcock Ingram Limited Dolutegravir and Its Combination Drug Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Adcock Ingram Limited Recent Developments and Future Plans
2.3 Aurobindo Pharma
2.3.1 Aurobindo Pharma Details
2.3.2 Aurobindo Pharma Major Business
2.3.3 Aurobindo Pharma Dolutegravir and Its Combination Drug Product and Solutions
2.3.4 Aurobindo Pharma Dolutegravir and Its Combination Drug Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Aurobindo Pharma Recent Developments and Future Plans
2.4 Cipla
2.4.1 Cipla Details
2.4.2 Cipla Major Business
2.4.3 Cipla Dolutegravir and Its Combination Drug Product and Solutions
2.4.4 Cipla Dolutegravir and Its Combination Drug Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Cipla Recent Developments and Future Plans
2.5 Emcure Pharmaceuticals
2.5.1 Emcure Pharmaceuticals Details
2.5.2 Emcure Pharmaceuticals Major Business
2.5.3 Emcure Pharmaceuticals Dolutegravir and Its Combination Drug Product and Solutions
2.5.4 Emcure Pharmaceuticals Dolutegravir and Its Combination Drug Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Emcure Pharmaceuticals Recent Developments and Future Plans
2.6 LAURUS Labs
2.6.1 LAURUS Labs Details
2.6.2 LAURUS Labs Major Business
2.6.3 LAURUS Labs Dolutegravir and Its Combination Drug Product and Solutions
2.6.4 LAURUS Labs Dolutegravir and Its Combination Drug Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 LAURUS Labs Recent Developments and Future Plans
2.7 Mylan
2.7.1 Mylan Details
2.7.2 Mylan Major Business
2.7.3 Mylan Dolutegravir and Its Combination Drug Product and Solutions
2.7.4 Mylan Dolutegravir and Its Combination Drug Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Mylan Recent Developments and Future Plans
2.8 Ranbaxy Pharmaceuticals
2.8.1 Ranbaxy Pharmaceuticals Details
2.8.2 Ranbaxy Pharmaceuticals Major Business
2.8.3 Ranbaxy Pharmaceuticals Dolutegravir and Its Combination Drug Product and Solutions
2.8.4 Ranbaxy Pharmaceuticals Dolutegravir and Its Combination Drug Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Ranbaxy Pharmaceuticals Recent Developments and Future Plans
2.9 Shanghai Desano Pharmaceuticals
2.9.1 Shanghai Desano Pharmaceuticals Details
2.9.2 Shanghai Desano Pharmaceuticals Major Business
2.9.3 Shanghai Desano Pharmaceuticals Dolutegravir and Its Combination Drug Product and Solutions
2.9.4 Shanghai Desano Pharmaceuticals Dolutegravir and Its Combination Drug Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 Shanghai Desano Pharmaceuticals Recent Developments and Future Plans
2.10 JNJ
2.10.1 JNJ Details
2.10.2 JNJ Major Business
2.10.3 JNJ Dolutegravir and Its Combination Drug Product and Solutions
2.10.4 JNJ Dolutegravir and Its Combination Drug Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 JNJ Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Dolutegravir and Its Combination Drug Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Dolutegravir and Its Combination Drug Players Market Share
3.2.2 Top 10 Dolutegravir and Its Combination Drug Players Market Share
3.2.3 Market Competition Trend
3.3 Dolutegravir and Its Combination Drug Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Dolutegravir and Its Combination Drug Revenue and Market Share by Type (2016-2021)
4.2 Global Dolutegravir and Its Combination Drug Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Dolutegravir and Its Combination Drug Revenue Market Share by Application (2016-2021)
5.2 Dolutegravir and Its Combination Drug Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Dolutegravir and Its Combination Drug Revenue by Type (2016-2026)
6.2 North America Dolutegravir and Its Combination Drug Revenue by Application (2016-2026)
6.3 North America Dolutegravir and Its Combination Drug Market Size by Country
6.3.1 North America Dolutegravir and Its Combination Drug Revenue by Country (2016-2026)
6.3.2 United States Dolutegravir and Its Combination Drug Market Size and Forecast (2016-2026)
6.3.3 Canada Dolutegravir and Its Combination Drug Market Size and Forecast (2016-2026)
6.3.4 Mexico Dolutegravir and Its Combination Drug Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Dolutegravir and Its Combination Drug Revenue by Type (2016-2026)
7.2 Europe Dolutegravir and Its Combination Drug Revenue by Application (2016-2026)
7.3 Europe Dolutegravir and Its Combination Drug Market Size by Country
7.3.1 Europe Dolutegravir and Its Combination Drug Revenue by Country (2016-2026)
7.3.2 Germany Dolutegravir and Its Combination Drug Market Size and Forecast (2016-2026)
7.3.3 France Dolutegravir and Its Combination Drug Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Dolutegravir and Its Combination Drug Market Size and Forecast (2016-2026)
7.3.5 Russia Dolutegravir and Its Combination Drug Market Size and Forecast (2016-2026)
7.3.6 Italy Dolutegravir and Its Combination Drug Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Dolutegravir and Its Combination Drug Revenue by Type (2016-2026)
8.2 Asia-Pacific Dolutegravir and Its Combination Drug Revenue by Application (2016-2026)
8.3 Asia-Pacific Dolutegravir and Its Combination Drug Market Size by Region
8.3.1 Asia-Pacific Dolutegravir and Its Combination Drug Revenue by Region (2016-2026)
8.3.2 China Dolutegravir and Its Combination Drug Market Size and Forecast (2016-2026)
8.3.3 Japan Dolutegravir and Its Combination Drug Market Size and Forecast (2016-2026)
8.3.4 South Korea Dolutegravir and Its Combination Drug Market Size and Forecast (2016-2026)
8.3.5 India Dolutegravir and Its Combination Drug Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Dolutegravir and Its Combination Drug Market Size and Forecast (2016-2026)
8.3.7 Australia Dolutegravir and Its Combination Drug Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Dolutegravir and Its Combination Drug Revenue by Type (2016-2026)
9.2 South America Dolutegravir and Its Combination Drug Revenue by Application (2016-2026)
9.3 South America Dolutegravir and Its Combination Drug Market Size by Country
9.3.1 South America Dolutegravir and Its Combination Drug Revenue by Country (2016-2026)
9.3.2 Brazil Dolutegravir and Its Combination Drug Market Size and Forecast (2016-2026)
9.3.3 Argentina Dolutegravir and Its Combination Drug Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Dolutegravir and Its Combination Drug Revenue by Type (2016-2026)
10.2 Middle East & Africa Dolutegravir and Its Combination Drug Revenue by Application (2016-2026)
10.3 Middle East & Africa Dolutegravir and Its Combination Drug Market Size by Country
10.3.1 Middle East & Africa Dolutegravir and Its Combination Drug Revenue by Country (2016-2026)
10.3.2 Turkey Dolutegravir and Its Combination Drug Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Dolutegravir and Its Combination Drug Market Size and Forecast (2016-2026)
10.3.4 UAE Dolutegravir and Its Combination Drug Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer

List of Tables
Table 1. Global Dolutegravir and Its Combination Drug Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Dolutegravir and Its Combination Drug Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Dolutegravir and Its Combination Drug Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Dolutegravir and Its Combination Drug Revenue (USD Million) by Region (2016-2021)
Table 5. Global Dolutegravir and Its Combination Drug Revenue Market Share by Region (2021-2026)
Table 6. ViiV Healthcare (GSK) Corporate Information, Head Office, and Major Competitors
Table 7. ViiV Healthcare (GSK) Major Business
Table 8. ViiV Healthcare (GSK) Dolutegravir and Its Combination Drug Product and Solutions
Table 9. ViiV Healthcare (GSK) Dolutegravir and Its Combination Drug Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Adcock Ingram Limited Corporate Information, Head Office, and Major Competitors
Table 11. Adcock Ingram Limited Major Business
Table 12. Adcock Ingram Limited Dolutegravir and Its Combination Drug Product and Solutions
Table 13. Adcock Ingram Limited Dolutegravir and Its Combination Drug Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Aurobindo Pharma Corporate Information, Head Office, and Major Competitors
Table 15. Aurobindo Pharma Major Business
Table 16. Aurobindo Pharma Dolutegravir and Its Combination Drug Product and Solutions
Table 17. Aurobindo Pharma Dolutegravir and Its Combination Drug Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Cipla Corporate Information, Head Office, and Major Competitors
Table 19. Cipla Major Business
Table 20. Cipla Dolutegravir and Its Combination Drug Product and Solutions
Table 21. Cipla Dolutegravir and Its Combination Drug Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Emcure Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 23. Emcure Pharmaceuticals Major Business
Table 24. Emcure Pharmaceuticals Dolutegravir and Its Combination Drug Product and Solutions
Table 25. Emcure Pharmaceuticals Dolutegravir and Its Combination Drug Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. LAURUS Labs Corporate Information, Head Office, and Major Competitors
Table 27. LAURUS Labs Major Business
Table 28. LAURUS Labs Dolutegravir and Its Combination Drug Product and Solutions
Table 29. LAURUS Labs Dolutegravir and Its Combination Drug Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Mylan Corporate Information, Head Office, and Major Competitors
Table 31. Mylan Major Business
Table 32. Mylan Dolutegravir and Its Combination Drug Product and Solutions
Table 33. Mylan Dolutegravir and Its Combination Drug Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Ranbaxy Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 35. Ranbaxy Pharmaceuticals Major Business
Table 36. Ranbaxy Pharmaceuticals Dolutegravir and Its Combination Drug Product and Solutions
Table 37. Ranbaxy Pharmaceuticals Dolutegravir and Its Combination Drug Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. Shanghai Desano Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 39. Shanghai Desano Pharmaceuticals Major Business
Table 40. Shanghai Desano Pharmaceuticals Dolutegravir and Its Combination Drug Product and Solutions
Table 41. Shanghai Desano Pharmaceuticals Dolutegravir and Its Combination Drug Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. JNJ Corporate Information, Head Office, and Major Competitors
Table 43. JNJ Major Business
Table 44. JNJ Dolutegravir and Its Combination Drug Product and Solutions
Table 45. JNJ Dolutegravir and Its Combination Drug Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. Global Dolutegravir and Its Combination Drug Revenue (USD Million) by Players (2019-2021)
Table 47. Global Dolutegravir and Its Combination Drug Revenue Share by Players (2019-2021)
Table 48. Breakdown of Dolutegravir and Its Combination Drug by Company Type (Tier 1, Tier 2 and Tier 3)
Table 49. Dolutegravir and Its Combination Drug Players Head Office, Products and Services Provided
Table 50. Dolutegravir and Its Combination Drug Mergers & Acquisitions in the Past Five Years
Table 51. Dolutegravir and Its Combination Drug New Entrants and Expansion Plans
Table 52. Global Dolutegravir and Its Combination Drug Revenue (USD Million) by Type (2016-2021)
Table 53. Global Dolutegravir and Its Combination Drug Revenue Share by Type (2016-2021)
Table 54. Global Dolutegravir and Its Combination Drug Revenue Forecast by Type (2021-2026)
Table 55. Global Dolutegravir and Its Combination Drug Revenue by Application (2016-2021)
Table 56. Global Dolutegravir and Its Combination Drug Revenue Forecast by Application (2021-2026)
Table 57. North America Dolutegravir and Its Combination Drug Revenue by Type (2016-2021) & (USD Million)
Table 58. North America Dolutegravir and Its Combination Drug Revenue by Type (2021-2026) & (USD Million)
Table 59. North America Dolutegravir and Its Combination Drug Revenue by Application (2016-2021) & (USD Million)
Table 60. North America Dolutegravir and Its Combination Drug Revenue by Application (2021-2026) & (USD Million)
Table 61. North America Dolutegravir and Its Combination Drug Revenue by Country (2016-2021) & (USD Million)
Table 62. North America Dolutegravir and Its Combination Drug Revenue by Country (2021-2026) & (USD Million)
Table 63. Europe Dolutegravir and Its Combination Drug Revenue by Type (2016-2021) & (USD Million)
Table 64. Europe Dolutegravir and Its Combination Drug Revenue by Type (2021-2026) & (USD Million)
Table 65. Europe Dolutegravir and Its Combination Drug Revenue by Application (2016-2021) & (USD Million)
Table 66. Europe Dolutegravir and Its Combination Drug Revenue by Application (2021-2026) & (USD Million)
Table 67. Europe Dolutegravir and Its Combination Drug Revenue by Country (2016-2021) & (USD Million)
Table 68. Europe Dolutegravir and Its Combination Drug Revenue by Country (2021-2026) & (USD Million)
Table 69. Asia-Pacific Dolutegravir and Its Combination Drug Revenue by Type (2016-2021) & (USD Million)
Table 70. Asia-Pacific Dolutegravir and Its Combination Drug Revenue by Type (2021-2026) & (USD Million)
Table 71. Asia-Pacific Dolutegravir and Its Combination Drug Revenue by Application (2016-2021) & (USD Million)
Table 72. Asia-Pacific Dolutegravir and Its Combination Drug Revenue by Application (2021-2026) & (USD Million)
Table 73. Asia-Pacific Dolutegravir and Its Combination Drug Revenue by Region (2016-2021) & (USD Million)
Table 74. Asia-Pacific Dolutegravir and Its Combination Drug Revenue by Region (2021-2026) & (USD Million)
Table 75. South America Dolutegravir and Its Combination Drug Revenue by Type (2016-2021) & (USD Million)
Table 76. South America Dolutegravir and Its Combination Drug Revenue by Type (2021-2026) & (USD Million)
Table 77. South America Dolutegravir and Its Combination Drug Revenue by Application (2016-2021) & (USD Million)
Table 78. South America Dolutegravir and Its Combination Drug Revenue by Application (2021-2026) & (USD Million)
Table 79. South America Dolutegravir and Its Combination Drug Revenue by Country (2016-2021) & (USD Million)
Table 80. South America Dolutegravir and Its Combination Drug Revenue by Country (2021-2026) & (USD Million)
Table 81. Middle East & Africa Dolutegravir and Its Combination Drug Revenue by Type (2016-2021) & (USD Million)
Table 82. Middle East & Africa Dolutegravir and Its Combination Drug Revenue by Type (2021-2026) & (USD Million)
Table 83. Middle East & Africa Dolutegravir and Its Combination Drug Revenue by Application (2016-2021) & (USD Million)
Table 84. Middle East & Africa Dolutegravir and Its Combination Drug Revenue by Application (2021-2026) & (USD Million)
Table 85. Middle East & Africa Dolutegravir and Its Combination Drug Revenue by Country (2016-2021) & (USD Million)
Table 86. Middle East & Africa Dolutegravir and Its Combination Drug Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Dolutegravir and Its Combination Drug Picture
Figure 2. Global Dolutegravir and Its Combination Drug Revenue Market Share by Type in 2020
Figure 3. Dolutegravir
Figure 4. Abacavir/Dolutegravir/Lamivudine
Figure 5. Dolutegravir/Rilpivirine
Figure 6. Dolutegravir and Its Combination Drug Revenue Market Share by Application in 2020
Figure 7. Hospital Picture
Figure 8. Clinic Picture
Figure 9. Drug Center Picture
Figure 10. Other Picture
Figure 11. Global Dolutegravir and Its Combination Drug Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 12. Global Dolutegravir and Its Combination Drug Revenue and Forecast (2016-2026) & (USD Million)
Figure 13. Global Dolutegravir and Its Combination Drug Revenue Market Share by Region (2016-2026)
Figure 14. Global Dolutegravir and Its Combination Drug Revenue Market Share by Region in 2020
Figure 15. North America Dolutegravir and Its Combination Drug Revenue (USD Million) and Growth Rate (2016-2026)
Figure 16. Europe Dolutegravir and Its Combination Drug Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. Asia-Pacific Dolutegravir and Its Combination Drug Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. South America Dolutegravir and Its Combination Drug Revenue (USD Million) and Growth Rate (2016-2026)
Figure 19. Middle East and Africa Dolutegravir and Its Combination Drug Revenue (USD Million) and Growth Rate (2016-2026)
Figure 20. Dolutegravir and Its Combination Drug Market Drivers
Figure 21. Dolutegravir and Its Combination Drug Market Restraints
Figure 22. Dolutegravir and Its Combination Drug Market Trends
Figure 23. ViiV Healthcare (GSK) Recent Developments and Future Plans
Figure 24. Adcock Ingram Limited Recent Developments and Future Plans
Figure 25. Aurobindo Pharma Recent Developments and Future Plans
Figure 26. Cipla Recent Developments and Future Plans
Figure 27. Emcure Pharmaceuticals Recent Developments and Future Plans
Figure 28. LAURUS Labs Recent Developments and Future Plans
Figure 29. Mylan Recent Developments and Future Plans
Figure 30. Ranbaxy Pharmaceuticals Recent Developments and Future Plans
Figure 31. Shanghai Desano Pharmaceuticals Recent Developments and Future Plans
Figure 32. JNJ Recent Developments and Future Plans
Figure 33. Global Dolutegravir and Its Combination Drug Revenue Share by Players in 2020
Figure 34. Dolutegravir and Its Combination Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 35. Global Top 3 Players Dolutegravir and Its Combination Drug Revenue Market Share in 2020
Figure 36. Global Top 10 Players Dolutegravir and Its Combination Drug Revenue Market Share in 2020
Figure 37. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 38. Global Dolutegravir and Its Combination Drug Revenue Share by Type in 2020
Figure 39. Global Dolutegravir and Its Combination Drug Market Share Forecast by Type (2021-2026)
Figure 40. Global Dolutegravir and Its Combination Drug Revenue Share by Application in 2020
Figure 41. Global Dolutegravir and Its Combination Drug Market Share Forecast by Application (2021-2026)
Figure 42. North America Dolutegravir and Its Combination Drug Sales Market Share by Type (2016-2026)
Figure 43. North America Dolutegravir and Its Combination Drug Sales Market Share by Application (2016-2026)
Figure 44. North America Dolutegravir and Its Combination Drug Revenue Market Share by Country (2016-2026)
Figure 45. United States Dolutegravir and Its Combination Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 46. Canada Dolutegravir and Its Combination Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 47. Mexico Dolutegravir and Its Combination Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 48. Europe Dolutegravir and Its Combination Drug Sales Market Share by Type (2016-2026)
Figure 49. Europe Dolutegravir and Its Combination Drug Sales Market Share by Application (2016-2026)
Figure 50. Europe Dolutegravir and Its Combination Drug Revenue Market Share by Country (2016-2026)
Figure 51. Germany Dolutegravir and Its Combination Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. France Dolutegravir and Its Combination Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. United Kingdom Dolutegravir and Its Combination Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. Russia Dolutegravir and Its Combination Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Italy Dolutegravir and Its Combination Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. Asia-Pacific Dolutegravir and Its Combination Drug Sales Market Share by Type (2016-2026)
Figure 57. Asia-Pacific Dolutegravir and Its Combination Drug Sales Market Share by Application (2016-2026)
Figure 58. Asia-Pacific Dolutegravir and Its Combination Drug Revenue Market Share by Region (2016-2026)
Figure 59. China Dolutegravir and Its Combination Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. Japan Dolutegravir and Its Combination Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. South Korea Dolutegravir and Its Combination Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. India Dolutegravir and Its Combination Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. Southeast Asia Dolutegravir and Its Combination Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. Australia Dolutegravir and Its Combination Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. South America Dolutegravir and Its Combination Drug Sales Market Share by Type (2016-2026)
Figure 66. South America Dolutegravir and Its Combination Drug Sales Market Share by Application (2016-2026)
Figure 67. South America Dolutegravir and Its Combination Drug Revenue Market Share by Country (2016-2026)
Figure 68. Brazil Dolutegravir and Its Combination Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 69. Argentina Dolutegravir and Its Combination Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 70. Middle East and Africa Dolutegravir and Its Combination Drug Sales Market Share by Type (2016-2026)
Figure 71. Middle East and Africa Dolutegravir and Its Combination Drug Sales Market Share by Application (2016-2026)
Figure 72. Middle East and Africa Dolutegravir and Its Combination Drug Revenue Market Share by Country (2016-2026)
Figure 73. Turkey Dolutegravir and Its Combination Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 74. Saudi Arabia Dolutegravir and Its Combination Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 75. UAE Dolutegravir and Its Combination Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 76. Methodology
Figure 77. Research Process and Data Source

---